Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Discuss your medical history, current condition, and treatment goals
On June 24, 2026, Novo Nordisk, a global leader in diabetes and obesity treatments, officially launched its flagship weight-loss drug Wegovy (Semaglutide) in India
Ozempic injections have been shown to reduce major cardiovascular events in people with type 2 diabetes and established cardiovascular disease
Pro: Lixisenatide is the only GLP analog that does not have a boxed warning about the risk of thyroid C-cell tumors
This review aims to synthesise and compare the safety profiles of incretin-based therapies, including GLP-1 receptor agonists for Obesity and Type 2 Diabetes, by integrating clinical and mechanistic evidence and to identify evidence-based strategies for risk mitigation and safe clinical use
For instance, as per the data published by the CDC in November 2023, more than 1 in 3 Americans are at increased risk for type 2 diabetes
